Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Nimbus Therapeutics

Request full access

Applying deep computational chemistry expertise to create novel small molecule therapeutics

Cambridge, United StatesFounded 2009Biotech & Life Sciences

About Nimbus Therapeutics

Nimbus Therapeutics is a biotechnology company focused on designing small molecule therapeutics to address significant challenges in drug development. The company operates in the pharmaceutical and biotechnology market, serving patients with unmet medical needs. Nimbus employs a unique collective expertise to push the boundaries of drug discovery and development. The business model revolves around research and development of breakthrough medicines, backed by substantial investments from prominent life science investors like Atlas Venture, SR One, Lilly Ventures, Bill Gates, Pfizer Venture Investments, and Lightstone Ventures. Nimbus generates revenue through partnerships, licensing agreements, and milestone payments from pharmaceutical companies. The company has secured multiple rounds of financing, including a $24 million Series A in 2011, a $43 million Series B in 2015, and an additional $65 million in 2018.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
101
Open positions
None listed
Dealroom signal
38.8/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Drug Development, DNA, Genetics and genomics, Genome Engineering, Rumoured $1B, Biotech and Pharma, Techbio, Hard Tech, DT and LS
Business model
Manufacturing

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Sep 2023 $210M $840M Atlas Venture · Lightstone Ventures · RA Capital Management · Pfizer Ventures ↗
ACQUISITIONOther financing Dec 2022 $0 — Takeda ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Nimbus Therapeutics website traffic

Latest recorded traffic for Nimbus Therapeutics is 12K monthly website visits, up 20% over the last three months. Nimbus Therapeutics's team grew 3.1% over the past year.

Latest monthly visits12K 3-month web change+20% 1-year team growth+3.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Nimbus Therapeutics in the Cambridge ecosystem

Live from Dealroom

The Nimbus Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

18 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

Series A4 investors entered at this stage

  • Pfizer Ventures
  • SR One
  • Lilly Ventures
  • Lightstone Ventures

Series B and later10 investors entered at this stage

  • BVF Partners
  • Commodore Capital
  • RA Capital Management
  • Logos Capital
  • Access Biotechnology
  • Surveyor Capital
  • SV Health Investors
  • Bain Capital Life Sciences
  • GV
  • Gates Frontier

Other known investors1 additional known investor

  • Takeda
Team profiled 21 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Nimbus Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.